Norma C Gutiérrez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/399599/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomics of Plasma Cell Leukemia. Cancers, 2022, 14, 1594.	1.7	3
2	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	2.0	13
3	Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells, 2021, 10, 336.	1.8	48
4	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. Cells, 2021, 10, 559.	1.8	2
5	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clinical Cancer Research, 2017, 23, 6602-6615.	3.2	25
6	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. Journal of Hematology and Oncology, 2017, 10, 92.	6.9	23
7	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 2003.	1.8	59
8	Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. American Journal of Pathology, 2016, 186, 2171-2182.	1.9	35
9	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 207-217.	3.2	21
10	Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability. PLoS ONE, 2015, 10, e0121581.	1.1	44
11	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer, 2015, 15, 238.	1.1	16
12	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 353-366.	0.9	22
13	Response to imatinib mesylate in patients with hypereosinophilic syndrome. International Journal of Hematology, 2012, 96, 320-326.	0.7	16